Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | TOP2A | P11388 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440787 | 1.00 | AKR1C3 (0.54) | AKR1C3AKR1C2AKR1C1TOP2AMAPT | |
| SCHEMBL29440785 | 1.00 | AKR1C3 (0.54) | AKR1C3AKR1C2AKR1C1TOP2AMAPT | |
| SCHEMBL5842306 | 0.89 | KDM4E (0.57) | AKR1C3AKR1C2AKR1C1TOP2AMAPT | |
| SCHEMBL3679916 | 0.88 | NPC1 (0.53) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL313075 | 0.86 | KDM4E (0.58) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL16203168 | 0.84 | KDM6B (0.67) | AKR1C3AKR1C2AKR1C1MAPTKDM4E | |
| SCHEMBL6469733 | 0.84 | MAOA (0.49) | AKR1C3AKR1C2AKR1C1TOP2AMAPT | |
| SCHEMBL6469479 | 0.84 | MAOA (0.59) | AKR1C3AKR1C2AKR1C1TOP2AMAPT | |
| SCHEMBL5842491 | 0.84 | MAOA (0.51) | AKR1C3AKR1C2AKR1C1TOP2AMAPT | |
| SCHEMBL2882726 | 0.82 | NPC1 (0.58) | MAPTKDM4ENPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114085194-B | Preparation method of 2- (2-hydroxyphenyl) -4H- [1,3] -benzoxazine-4-one | 青岛科技大学 | 2023-07-18 | — | — | CN | claimed |
| CN-115057827-B | Deferasirox derivative, synthesis method thereof and application thereof in preparation of iron overload hepatocellular carcinoma diagnosis and treatment drugs | 河南大学 | 2023-06-30 | — | — | CN | claimed |
| CN-115057827-A | Deferasirox derivative, synthesis method thereof and application thereof in preparation of medicines for diagnosing and treating iron-overload hepatocellular carcinoma | 河南大学 | 2022-09-16 | — | — | CN | claimed |
| CN-114085194-A | Preparation method of 2- (2-hydroxyphenyl) -4H- [1,3] -benzoxazine-4-one | 青岛科技大学 | 2022-02-25 | — | — | CN | claimed |
| US-11078167-B2 | Process for the preparation of Deferasirox | AUROBINDO PHARMA LTD (IN) | 2021-08-03 | — | — | US | claimed |
| US-20200207725-A1 | A process for the preparation of Deferasirox | AUROBINDO PHARMA LTD. (IN) | 2020-07-02 | — | — | US | claimed |
| WO-2019016637-A1 | A PROCESS FOR THE PREPARATION OF DEFERASIROX | AUROBINDO PHARMA LIMITED (IN) | 2019-01-24 | — | — | WO | claimed |
| WO-2016203488-A1 | PREPARATION OF NOVEL DEFERASIROX ANALOGUES FOR ANTIMALARIAL ACTIVITY | HAVALDAR FREDDY H (IN) | 2016-12-22 | — | — | WO | claimed |
| CN-103554040-B | A kind of preparation method of deferasirox derivative | NANJING JINGLONG DRUG RESEARCH AND DEVELOPMENT CO., LTD. (CN) | 2015-12-02 | — | — | CN | claimed |
| EP-2632907-B1 | PROCESS FOR PREPARING 2-(2-HYDROXYPHENYL)-BENZ[1,3]OXAZIN-4-ONE AND ITS USE FOR PREPARING DEFERASIROX | DAVULURI RAMAMOHAN RAO (IN) | 2015-10-14 | — | — | EP | claimed |
| WO-2012131017-A1 | PROCESS FOR THE PRODUCTION OF DEFERASIROX | ERREGIERRE S.P.A. (IT) | 2012-10-04 | — | — | WO | claimed |
| US-8129421-B2 | Method for preparing 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid | Farmak, A S (CZ) | 2012-03-06 | — | — | US | claimed |
| WO-2012025935-A2 | A PROCESS FOR THE PREPARATION OF 2-(2-HYDROXYPHENYL)-BENZ[1,3]OXAZIN-4-ONE AND ITS USE FOR PREPARATION OF 4-[3, 5-BIS (2-HYDROXYPHENYL)-1H-1, 2, 4-TRIAZOL-1-YL] BENZOIC ACID | DAVULURI RAMAMOHAN RAO (IN) | 2012-03-01 | — | — | WO | claimed |
| US-20110097413-A1 | SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-04-28 | — | — | US | claimed |
| EP-2291360-A2 | SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF | Actavis Group PTC ehf. (IS) | 2011-03-09 | — | — | EP | claimed |
| WO-2011021218-A2 | PROCESS FOR THE PREPARATION OF 4-[3,5-BIS(2-HYDROXYPHENYL)-1H-1,2,4-TRIAZOL-1-YL]-BENZOIC ACID AND ITS AMINE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | claimed |
| US-20110034702-A1 | METHOD FOR PREPARING 4-[3,5-BIS(2-HYDROXYPHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID | FARMAK, A.S. (CZ) | 2011-02-10 | — | — | US | claimed |
| WO-2010023685-A2 | CRYSTALLINE FORM OF 2-(2-HYDROXY PHENYL)BENZ[E][1,3]OXAZIN-4-ONE, PROCESS FOR THE SAME AND USE FOR PRODUCING 4-(3,5-BIS(2-HYDROXYPHENYL)-1H-1,2,4-TRIAZOL-1-YL)BENZOIC ACID | MATRIX LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | WO | claimed |
| WO-2009130604-A2 | SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2009-10-29 | — | — | WO | claimed |
| WO-2009094956-A1 | A METHOD FOR PREPARING 4-[3,5-BIS(2-HYDROXYPHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID | FARMAK, A.S. (CZ) | 2009-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034702-A1 | METHOD FOR PREPARING 4-[3,5-BIS(2-HYDROXYPHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID | HAO2, HPD, HAO1 | AKR1C3 522/4885AKR1C2 399/4885AKR1C1 318/4885 |
| US-20110097413-A1 | SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF | SF3A2, HAMP, SRSF2 | AKR1C3 1426/4885AKR1C2 1527/4885AKR1C1 1596/4885 |
| US-11078167-B2 | Process for the preparation of Deferasirox | HAMP, F5, CYP4F11 | AKR1C3 766/4885AKR1C2 626/4885AKR1C1 620/4885 |
| US-20200207725-A1 | A process for the preparation of Deferasirox | HAMP, CYP4F11, F5 | AKR1C3 949/4885AKR1C2 749/4885AKR1C1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.